Literature DB >> 14601263

Massive obstetric hemorrhage.

Zoltán Papp1.   

Abstract

Massive obstetric haemorrhage is a major cause of maternal death and morbidity; abruption of the placenta, placenta praevia and postpartum haemorrhage being the main causes of haemorrhages. A delay in the correction of hypovolaemia, diagnosis and treatment of defective coagulation and/or surgical control of bleeding are the avoidable factors in most maternal deaths caused by haemorrhage. The main goal is to maintain effective circulating intravascular volume by prompt and adequate replacement of blood, crystalloids or fresh-frozen plasma through more than one intravenous line (it might be necessary to pump blood under pressure) with constant monitoring of the pulse rate and the arterial blood pressure. The rapid correction of hypovolaemia with crystalloids and red cells is the first priority, followed by blood component therapy. Oxytocin and prostaglandin will correct uterine atony, and appropriate surgical intervention is required for traumatic bleeding. Ligation of the uterine arteries, ovarian arteries and hypogastric arteries will usually control uterine bleeding and arterial embolization is also effective. Hysterectomy should also be considered in severe cases. All gynecologists should be able to perform without delay the operative maneuvers which are necessary to control the bleeding, including hypogastric artery ligation, or even emergency hysterectomy. This topic may have received little attention because it is perceived as being associated with maternal morbidity rather than mortality in developed countries; it is only recently that the extent and importance of postnatal maternal morbidity has been recognized.

Entities:  

Mesh:

Year:  2003        PMID: 14601263     DOI: 10.1515/JPM.2003.063

Source DB:  PubMed          Journal:  J Perinat Med        ISSN: 0300-5577            Impact factor:   1.901


  1 in total

1.  Uterine artery embolization for primary postpartum hemorrhage.

Authors:  Tae-Hee Kim; Hae-Hyeog Lee; Jun-Mo Kim; Ae-Li Ryu; Soo-Ho Chung; Woo Seok Lee
Journal:  Iran J Reprod Med       Date:  2013-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.